A new drug combo recently approved by the Food & Drug Administration can halt lung cancer in its treacherous tracks — for over 40% longer than previously possible, a wide-ranging trial funded by pharmaceutical giant Janssen showed. Doctors are hailing the breakthrough as “amazing.”

According to the American Cancer Society, around 20% of all deaths from cancer in the United States are a result of lung cancer. It’s one of the most common forms of cancer in the U.S., as well as being the deadliest.